Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132126 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT06132126 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 66 participants.
The verdict
NCT06132126, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.
Interventions
- DRUG Placebo
- DRUG LY3938577
- DRUG Insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2024-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06132126
The ClinicalTrials.gov registry entry for NCT06132126 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06132126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06132126 about?
NCT06132126 is a clinical study titled "A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus". The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks f...
What is the current status of trial NCT06132126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2023-11-17. Estimated completion is 2024-06-28.
What interventions are being tested in trial NCT06132126?
The interventions under investigation include: Placebo (DRUG), LY3938577 (DRUG), Insulin degludec (DRUG).
Who is sponsoring clinical trial NCT06132126?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.